Louise J. Robertson

Louise J. Robertson

Auto-generated profile, based on publicly available information

Louise J. Robertson

School of Biomedicine and Robinson Research Institute University of Adelaide Adelaide Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
LRLouise J Robertson
Louise J Robertson
JMJulie S Moore
Julie S Moore
KBKevin Blighe
Kevin Blighe
Mark NgMark Ng
Mark Ng
NQNigel Quinn
Nigel Quinn
TMTara Moore
Tara Moore
Objective To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies. Design Nationwide serological study. Setting Northern Ireland, UK, May 2020–February 2021. Participants Plasma samples were collected from a diverse cohort of individuals from the general public (n=279), Northern Ireland healthcare workers (n=195), pre-pandemic blood donations and research studies (n=223) and through a convalescent plasma programme (n=183). Plasma donors (n=101) were followed with sequential samples over 11 months post-symptom onset. Main outcome measures SARS-CoV-2 antibody levels in plasma samples using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays over time. UK-RTC AbC-19 LFIA sensitivity and specificity, estimated using a three-reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples. Results We detected persistence of SARS-CoV-2 IgG antibodies for up to 10 months post-infection, across a minimum of two laboratory immunoassays. On the known positive cohort, the UK-RTC AbC-19 LFIA showed a sensitivity of 97.58% (95.28% to 98.95%) and on known negatives, showed specificity of 99.59% (98.53 % to 99.95%). Conclusions Through comprehensive analysis of a cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting over 46 weeks when assessed by EuroImmun ELISA, providing insight to antibody levels at later time points post-infection. We show good laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2 spike protein IgG antibody detection in a laboratory-based setting.


12 February 2025 in BMC Genomics
Verified
Journal Article
Open access
PDF file
YCYu C. J. Chey
Yu C. J. Chey
LGLuke Gierus
Luke Gierus
CLCaleb Lushington
Caleb Lushington
JAJayshen C. Arudkumar
Jayshen C. Arudkumar
AGAshleigh B. Geiger
Ashleigh B. Geiger
PTPaul Thomas
Paul Thomas
Ensuring sufficient gRNA transcript levels is critical for obtaining optimal CRISPR-Cas9 gene editing efficiency. The standard gRNA scaffold contains a sequence of four thymine nucleotides (4T), which is known to inhibit transcription from Pol III promoters such as the U6 promoter. Our study showed that using standard plasmid transfection protocols, the presence of these 4Ts did not significantly affect editing efficiency, as most of the gRNAs tested (55 gRNAs) achieved near-perfect editing outcomes. We observed that gRNAs with lower activity were T-rich and had reduced gRNA transcript levels. However, this issue can be effectively resolved by increasing transcript levels, which can be readily achieved by shortening the 4T sequences. In this study, we demonstrated this by modifying the sequences to 3TC. Although the 3TC scaffold modification did not improve editing efficiency for already efficient gRNAs when high vector quantities were available, it proved highly beneficial under conditions of limited vector availability, where the 3TC scaffold yielded higher editing efficiency. Additionally, we demonstrated that the 3TC scaffold is compatible with SpCas9 high-fidelity variants and ABEmax base editing, enhancing their editing efficiency. Another commonly used natural Cas9 variant, SaCas9, also benefited from the 3TC scaffold sequence modification, which increased gRNA transcription and subsequently improved editing activity. This modification was applied to the EDIT-101 therapeutic strategy, where it demonstrated marked improvements in performance. This study highlights the importance of shortening the 4T sequences in the gRNA scaffold to optimize gRNA transcript expression for enhanced CRISPR-Cas9 gene editing efficiency. This optimization is particularly important for therapeutic applications, where the quantity of vector is often limited, ensuring more effective and optimal outcomes.

18 March 2019 in Genes, Brain and Behavior
Verified
Journal Article
Closed access
PDF file
LRLouise Robertson
Louise Robertson
TFTravis Featherby
Travis Featherby
SHStuart Howell
Stuart Howell
JHJames Hughes
James Hughes
PTPaul Thomas
Paul Thomas

19 April 2026 in Evolutionary Applications
Verified
Journal Article
Open access
PDF file
ABAysegul Birand
Aysegul Birand
BHBruce A. Hay
Bruce A. Hay
MCMatthew Combs
Matthew Combs
LGLuke Gierus
Luke Gierus
KHKatherine E. Horak
Katherine E. Horak
APAntoinette J. Piaggio
Antoinette J. Piaggio
Invasive rodents cause severe ecosystem degradation on islands and can be challenging to eradicate. Current best‐practices rely on the application of toxic oral baits and have led to successful eradications and remarkable recoveries of native flora and fauna. Yet this single method is not universally applicable. Genetic biocontrol offers a suite of new solutions to potentially improve outcomes in the critical “last mile” of eradication. These approaches involve the release of genetically modified individuals of the target species to reduce population fitness over time. These include self‐limiting approaches which require multiple releases and self‐sustaining mechanisms (i.e., select gene‐drive systems) which could theoretically collapse populations after a single release. While gene drive systems have received significant attention, their development in vertebrates remains technically challenging, and their ecological and regulatory implications are still in active debate. In contrast, some non‐drive genetic biocontrol approaches, such as Y‐linked editors, fsRIDL, and Gravid Lethal, offer self‐limiting alternatives that may be more immediately deployable. These approaches could be used to supplement toxicant‐based methods and may also have reduced environmental risks and regulatory barriers. To evaluate the potential of these tools, we developed an individual‐based model simulating the eradication of house mice ( Mus musculus ) on a 125 ha island with an initial population of 11,000 individuals. We tested various combinations of genetic biocontrol release and effort strategies to understand tradeoffs between required effort and uncertainty for achieving successful eradication. Under certain effort strategies, we found that the Gravid Lethal approach performed the best, achieving eradication in < 2.3 years with intensive release effort and monitoring. Our findings suggest that integrating non‐drive genetic biocontrol into adaptive management frameworks could enhance the effectiveness and feasibility of rodent eradication programs. These tools are not replacements for toxicants but may serve as critical supplements—particularly in the “last mile” of eradication.